Advertisement
Advertisement
At close: 04:02PM EST
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 49.20 |
| Open | 49.14 |
| Bid | 50.21 x 4000 |
| Ask | 50.28 x 800 |
| Day's Range | 48.94 - 50.90 |
| 52 Week Range | 34.96 - 61.71 |
| Volume | |
| Avg. Volume | 38,694,285 |
| Market Cap | 282.686B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 13.04 |
| EPS (TTM) | 3.85 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | 1.60 (3.18%) |
| Ex-Dividend Date | Jan 27, 2022 |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-3% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Pfizer, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat3 days agoMorningstar
- Barrons.com
Pharma Exposure to the Ukraine War? Clinical Trials
Drug and medical-device companies don’t sell a lot to Russia and Ukraine, and sanctions haven’t been a problem. But both countries host a number of clinical trials. That could be a problem.
- Zacks
Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study
Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.
- Zacks
Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale
Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
